Takeaways from #ACR23 #ReviewCourse session on SpA Update: Radiographic and Non-Radiographic AS - Dr. Alexis Ogdie 1. Workup of inflammatory back pain: History, exam, CRP, HLA-B27, SI joint films, MRI pelvis (STIR images, no need for contrast). Response to NSAIDs not actually… https://t.co/M0W6UNsPxF https://t.co/7k3xl1RXZz

ABS0524: ⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) flares among high risk pts w/ axSpA ➡️active dz, HLAB27+, 2 or more AAU flares ⭐️CZP reduced AAU flare rate by 87% #ACR23 @RheumNow #ACRBest https://t.co/rW0N18agMO

Takeaways from #ACR23 #ReviewCourse session on Update on Relapsing Polychondritis - Dr. Marcela Ferrada 1. Be aware of common/uncommon manifestations (see slide). Affects more than just the ear!!! 2. Collagen II antibodies: not really sensitive or specific for diagnosis. Biopsy… https://t.co/f5xGtcMzk3 https://t.co/xVigSabXDb

Are we tapering steroids too rapidly? Real world experience: steroid tapering in severe #AAV based on #PEXIVAS protocol noted higher rates of dz progression, relapse, ESRD, death. Risk greatest when creatinine > 300umol/L and w/RTX induction #Plenary1 #ACR23 Abst#0725 #ACrBest https://t.co/Rtv7vkzUUD

ARDs increase risk for CVE in pregnancy, the highest being APS, SLE (with LN and APS) and RA. Close monitoring not only during but also after pregnancy is required. #Plenary #ACR23 https://t.co/W3CSjccSno

🔥 Absolute masterclass @philseo in the Clinical Year in Review #ACR23 ➡️ Certain subpopulations have lower risk of AE with Tofacitinib ➡️ Knee OA 📈 75% by 2050 ➡️ Exciting novel approaches in Rx of IA in development ➡️Better clinical trial endpoints needed for SLE https://t.co/5cjbZLPsCM

#Denosumab and what to do IF you stop it #ACR23 #osteoporosis #Bisphosphonate #CTX https://t.co/qwdQQjJJlb

Efficacy and Safety of Targeted Therapies in #VEXAS Syndrome: Retrospective Study from the French VEXAS Group :) #ACR23 late breaking poster - the figure says it all https://t.co/qahDDPLois https://t.co/ueb4aG8t77

ABS0538: ⭐️Characteristics of difficult-to-treat (D2T) axSpA pts: ➡️HLAB27(-) ➡️smokers ➡️shorter symptom duration ➡️more enthesitis ➡️IBD ➡️concomitant NSAID use ➡️Co-morbidities (HTN, HLD, fibro, depress/anxiety) #ACR23 @RheumNow https://t.co/TqEVBeaJpb

Yield of repeated assessments of SpA features in patients with CBP suspected of axSpA was modest for the increase of new definite axSpA diagnosis at 2y. Sacroilitis on MRI, good response to NSAIDs at BL most predictive of axSpA, ML Marques #ACR23 @RheumNow https://t.co/LQ5llML11M https://t.co/PYcCDypI7c

What a great pleasure to meet with the most amazing @RheumNow team on site at #ACR23 so glad to meet Shannon, Mitzi, John @Yuz6Yusof @Janetbirdope and looking forward to sharing the learnings from the conference https://t.co/ovXXLxDLKW

Pregnant women with ARDs esp. SLE nephritis and primary APS have significantly higher risks for acute CVEs compared to those without these conditions. 25-30% of CVEs occurred during the postpartum period, Dhital R Abst#0722 #ACR23 #ACRBest @RheumNow https://t.co/m9FjsAu64N https://t.co/1dyTzgH97A